Dyadic International (NASDAQ:DYAI) Stock Price Passes Below Fifty Day Moving Average – Here’s What Happened

Dyadic International Inc. (NASDAQ:DYAI) shares crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.76 and traded as low as $0.7401. Dyadic International shares last traded at $0.8010, with a volume of 394,340 shares changing hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $3.00.

Dyadic International Price Performance

The stock has a 50-day simple moving average of $0.76 and a 200 day simple moving average of $0.83. The company has a market cap of $29.19 million, a PE ratio of -3.48 and a beta of 1.17. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%.The business had revenue of $1.11 million for the quarter, compared to analyst estimates of $0.90 million. Equities analysts expect that Dyadic International Inc. will post 0.13 EPS for the current year.

Hedge Funds Weigh In On Dyadic International

Large investors have recently made changes to their positions in the stock. Bank of America Corp DE boosted its holdings in Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 26,965 shares during the period. Marathon Capital Management purchased a new stake in Dyadic International during the third quarter worth about $41,000. Geode Capital Management LLC lifted its position in shares of Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new stake in shares of Dyadic International during the third quarter worth about $190,000. Finally, Apis Capital Advisors LLC purchased a new position in shares of Dyadic International in the third quarter valued at approximately $1,817,000. 27.95% of the stock is currently owned by institutional investors and hedge funds.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.